Pneumococcal Infection Clinical Trials

2 recruiting

Pneumococcal Infection Trials at a Glance

6 actively recruiting trials for pneumococcal infection are listed on ClinicalTrialsFinder across 6 cities in 5 countries. The largest study group is Phase 3 with 2 trials, with the heaviest enrollment activity in Créteil, Bangkok, and Besançon. Lead sponsors running pneumococcal infection studies include Association Clinique Thérapeutique Infantile du val de Marne, Beijing Minhai Biotechnology Co., Ltd, and CanSino Biologics Inc..

Browse pneumococcal infection trials by phase

Treatments under study

About Pneumococcal Infection Clinical Trials

Looking for clinical trials for Pneumococcal Infection? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Pneumococcal Infection trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Pneumococcal Infection clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 16 of 6 trials

Recruiting

National, Non Interventional Study of Invasive Pneumococcal Disease in Children and Newborns

MortalityPneumococcal InfectionsPneumococcal Conjugate Vaccine+1 more
Association Clinique Thérapeutique Infantile du val de Marne2,500 enrolled1 locationNCT04664556
Recruiting
Phase 1

A Clinical Study of Novel Pneumococcal Vaccine V118C in Children (V118C-002)

Pneumococcal Infection
Merck Sharp & Dohme LLC210 enrolled14 locationsNCT07300267
Recruiting
Phase 4

Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults

Pneumococcal InfectionsAcute Febrile Illness
Centre Hospitalier Universitaire de Saint Etienne1,052 enrolled24 locationsNCT06822907
Recruiting
Phase 3

A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)

Bacterial InfectionsPneumococcal InfectionsStreptococcal Infections
CanSino Biologics Inc.600 enrolled3 locationsNCT07017777
Recruiting

In-depth Analysis of the Immune Responses in the Upper Respiratory Tract in Older Adults Infected or Colonized With Streptococcus Pneumoniae (Spn)

Pneumococcal InfectionsRespiratory Syncytial Virus (RSV) Infection
University Hospital, Geneva280 enrolled1 locationNCT06998251
Recruiting
Phase 3

A Phase 3 Study to Evaluate the Immunogenicity and Safety of Minhai's PCV13-DT/TT Vaccine As Compared to Pfizer's PCV13 Vaccine

Pneumococcal InfectionsPneumococcal Vaccines
Beijing Minhai Biotechnology Co., Ltd500 enrolled3 locationsNCT06608199